CAPRICOR THERAPEUTICS, INC. (CAPR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 32.96M USD | Liabilities, Current |
| Cash and equivalents | 20.94M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 217.00M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $32.96M | $20.94M | $217.00M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $33.64M | $105.42M | $173.19M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $35.84M | $287.85M | $30.28M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $28.15M | $19.51M | $79.06M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $28.40M | $23.24M | $99.56M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $22.34M | $28.79M | $115.98M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $21.03M | $11.29M | $140.23M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $20.48M | $68.38M | $16.65M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $22.35M | $10.69M | $18.77M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $26.38M | $6.21M | $33.70M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $31.27M | $14.69M | $24.79M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $32.93M | $8.98M | $19.54M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $35.15M | $9.84M | $27.96M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $37.13M | $10.61M | $34.57M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $23.59M | $9.60M | $31.82M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $23.19M | $8.41M | $38.20M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $19.55M | $16.39M | $35.02M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $14.32M | $58.33M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.13M | $34.89M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.99M | $40.84M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $3.17M | $38.08M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.75M | $41.88M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.97M | $32.67M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.28M | $35.30M | $0.00 | (m) | (m) | (m) |
| 2020-06-30 | (m) | $1.92M | $36.25M | $0.00 | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.32M | $13.22M | $0.00 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $897.99K | $3.90M | $5.99M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $960.72K | $6.83M | $0.00 | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.57M | $5.89M | $0.00 | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.50M | $7.17M | $0.00 | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.26M | $4.26M | $3.00M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.88M | $4.38M | $5.99M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.32M | $6.34M | $6.00M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.48M | $7.17M | $6.00M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.67M | $6.14M | $7.98M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $16.69M | $8.90M | $5.00M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $16.64M | $8.26M | $4.00M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.30M | $2.75M | $8.99M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $4.90M | $3.20M | $12.99M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.67M | $18.02M | $2.50M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.20M | $8.85M | $2.50M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $7.34M | $11.77M | $2.50M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.53M | $5.57M | $8.00M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.53M | $4.22M | $13.00M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $6.86M | $5.04M | $15.49M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $7.55M | $6.94M | $15.48M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $6.30M | $8.03M | $0.00 | (m) | (m) | (m) |
| 2014-09-30 | (m) | $6.19M | $9.81M | $325.32K | (m) | (m) | (m) |
| 2014-06-30 | (m) | $6.49M | $11.58M | $325.79K | (m) | (m) | (m) |
| 2014-03-31 | (m) | $6.30M | $12.98M | $326.23K | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.05M | $1.73M | $326.49K | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.18M | $71.03K | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.02M | $229.21K | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $649.13K | $285.03K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $330.98K | $46.72K | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $287.14K | $282.51K | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $267.06K | $777.18K | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $485.35K | $435.73K | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $541.45K | $1.04M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $717.82K | $2.61M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $436.27K | $3.26M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $2.12M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.07M | $3.38M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $4.44M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $5.56M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $3.18M | (m) | (m) | (m) | (m) |
| 2005-07-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2005-07-04 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |